Eli Lilly's Zepbound is set to dominate the global obesity market, offering new hope with its groundbreaking treatment for ...

On December 20, 2024, pharmaceutical company Eli Lilly announced that the FDA approved its first and only obstructive sleep ...

Imagine if you could eat your fill on Christmas day then dial down your appetite for January. Good news: such a prospect may ...

The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/95.C_N2kNfW.js ...

The obesity medication Zepbound can be used on-label to treat obstructive sleep apnea in adults with obesity, the FDA ...

Sugar substitutes, substance abuse, GLP-1 drugs, and the biggest clinical trials of the year—each had their place in our top ...

Indian pharmaceutical sector faces new challenges in 2025, from UCPMP implementation to global dynamics and opportunities in ...

In a world grappling with obesity and chronic disease, GLP-1 drugs like Ozempic are emerging as transformative game-changers.

The hitmaker, 50, was a guest on the show to promote his biopic Better Man, and during the interview, discussed the appearance of Jonno Davies, who plays his younger self.

Novo Nordisk retains a strong market position in a high-growth industry, with P/E multiples poised to expand. See why NVO ...